spacer
home > ebr > autumn 2012 > mindful medical monitoring
PAY PER VIEW SERVICE

 

Dear guest!

article: Mindful Medical Monitoring
format: Adobe Acrobat PDF file
cost: £

spacer

 
News and Press Releases

Oxford biotech firm secures £13.2m to develop world’s first treatment for rare, incurable and deadly disease

SynaptixBio, whose aim is to treat the genetic central nervous system disease TUBB4A-related leukodystrophy, has successfully raised £11.05m in its latest funding round to add to the £2.125m of seed funding from the last two years. Both rounds have come exclusively from private investment.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement